BSE filing, BSE: 544369. Summary written from the filing by ALFA Finder's alert engine.
Beezaasan Explotech Ltd: key numbers
- Share price
- ₹695.05
- Market cap
- ₹1,053 Cr
- Revenue (annual)
- ₹211.6 Cr
- Net profit (annual)
- ₹13.27 Cr
- P/E (TTM)
- 79.3×Sector 52.2×
- Promoter holding
- 75.00%
- FII holding
- 0.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beezaasan Explotech Ltd
All →Beezaasan Explotech Other Announcement
Beezaasan Explotech Ltd filed its quarterly shareholding pattern under Regulation 31. This routine regulatory disclosure details the promoter and public shareholding status.
Beezaasan Explotech Preferential Issue
Beezaasan Explotech's EGM on 13 October 2026 approved issuance of equity shares through a preferential private placement. Shareholders voted overwhelmingly in favour of the resolution.
Beezaasan Explotech Preferential Issue
Beezaasan Explotech Ltd held its EGM on October 13, 2026. Shareholders discussed the proposed issuance of equity shares through a preferential offer.
Beezaasan Explotech Annual General Meeting
Beezaasan Explotech issued a second corrigendum to its EGM notice for the proposed preferential issue. The proceeds of ₹29.28 crore are earmarked for working capital.
- Value
- ₹29.28 Cr
Beezaasan Explotech Board Meeting Outcome
Beezaasan Explotech Limited's board discussed a proposed acquisition of Asawara Earthtech Limited. The board deferred the decision, pending receipt of a valuation report from a registered valuer.
Beezaasan Explotech Board Meeting Date
Beezaasan Explotech will hold a board meeting on September 30, 2026, to consider and approve the acquisition of equity shares in Asawara Earthtech Limited.
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.